RARA and prostate carcinoma: The pan-RAR antagonist AGN194310 was more effective against patients’ prostate cancer cells and cell line cells than normal prostate fibroblasts and epithelial cells [65], and the RARγ antagonist AGN205728 was more effective against prostate cancer cell line cells than the normal prostate RWPE-1 cells [39].